ArticleMedicine2026
Contrast-enhanced ultrasound-guided liver biopsy with flow cytometry analysis for the diagnosis of secondary hemophagocytic syndrome: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleHemophagocytic lymphohistiocytosis (HLH) is a hereditary or acquired hyperinflammatory response syndrome. Diagnosis of HLH is challenging. PATIENT CONCERNS: We report a case of a 41-year-old male who was admitted to the hospital due to recurrent fever for 1 month and hematochezia for 2 days. DIAGNOSES: Positron emission tomography/computed tomography (PET/CT) showed multiple intrahepatic high-uptake nodules, and B-mode ultrasound could not accurately localize them. Contrast-enhanced ultrasound (CEUS)-guided liver biopsy combined with flow cytometry confirmed the final diagnosis of natural killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome. Pathological confirmation was made with a lymph node biopsy.
interventionsThe patient received the gemcitabine-dexamethasone-cisplatin (GDP) regimen and symptomatic supportive treatments. OUTCOMES: Unfortunately, the patient experienced persistent disease progression and passed away. LESSONS: HLH is a hyperinflammatory response syndrome caused by immune dysfunction. Lymphoma-associated hemophagocytic syndrome is the most common type of HLH. Diagnosis can be confirmed through CEUS-guided biopsy, flow cytometry analysis, and relevant clinical information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.